Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome

blonca9
Aug 5, 2024
1 min read

He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic condition, and how he views the company's protein upregulation approach as a broader platform.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight